The use of cyclosporine in dermatology: part I.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of American Academy of Dermatology

• Publication date

  2013-04-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaad.2010.02.063PMID 21093659
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation.

  2010cited by this paper
• EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

  2009cited by this paper
• Pyoderma gangrenosum following pacemaker insertion

  2009cited by this paper
• Rituximab in Severe Pemphigus

  2009cited by this paper
• European S3‐Guidelines on the systemic treatment of psoriasis vulgaris

  2009cited by this paper
• Behçet's disease--a contemporary review.

  2009cited by this paper
• What the first 10,000 patients with chronic urticaria have taught me: a personal journey.

  2009cited by this paper
• Guideline for the management of alopecia areata

  2009cited by this paper
• Systemic therapeutic options for severe atopic dermatitis

  2009cited by this paper
• Therapeutic effectiveness of various treatments for eosinophilic pustular folliculitis.

  2009cited by this paper
• Intractable wounds caused by pyoderma gangrenosum in a patient with critical limb ischemia treated with cyclosporine and adjuvant sympathectomy.

  2009cited by this paper
• Periungual lesions in pyoderma gangrenosum

  2009cited by this paper
• Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

  2009influential reference
• A non‐responsive chronic autoimmune urticaria in a 12‐year‐old autistic girl treated with cyclosporin

  2009cited by this paper
• Lichen planopilaris and psoriasis.

  2008cited by this paper
• Low‐dose and short‐term cyclosporine treatment in patients with chronic idiopathic urticaria: A clinical and immunological evaluation

  2008cited by this paper
• Preparation of a polymer surface coated with a gradient of quantum dots

  2008cited by this paper
• Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.

  2008cited by this paper
• The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis.

  2008cited by this paper
• Relapsing lichen actinicus successfully treated with cyclosporin

  2008cited by this paper
• Antipruritic effect of cyclosporine microemulsion in prurigo nodularis: Results of a case series

  2008cited by this paper
• Erosive lichen planus: two uncommon cases.

  2008cited by this paper
• Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata

  2008cited by this paper
• The treatment and prognosis of dermatomyositis: an updated review.

  2008cited by this paper
• Infantile pyoderma gangrenosum.

  2008cited by this paper
• A novel treatment for recalcitrant benign familial pemphigus

  2007cited by this paper
• Efficacy and Safety of Cyclophosphamide, Azathioprine, and Cyclosporine (Ciclosporin) as Adjuvant Drugs in Pemphigus Vulgaris

  2007cited by this paper
• Guidelines for evaluation and management of urticaria in adults and children

  2007cited by this paper
• Partial response to cyclosporine in a patient with Schnitzler's syndrome.

  2007cited by this paper
• Intermittent vs. continuous 1‐year cyclosporin use in chronic plaque psoriasis

  2007cited by this paper
• A case of dermatomyositis complicated with pneumomediastinum

  2007cited by this paper
• Palmoplantar lichen planus with umbilicated papules: an atypical case with rapid therapeutic response to cyclosporin

  2007cited by this paper
• Systemic treatment of severe atopic eczema: a systematic review.

  2007cited by this paper
• Efficacy and safety of long‐term treatment with cyclosporin A for atopic dermatitis

  2007cited by this paper
• Cyclosporin A Treatment Is Associated with Increased Serum Immunoglobulin E Levels in a Subgroup of Atopic Dermatitis Patients

  2007cited by this paper
• Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta‐analysis

  2007cited by this paper
• Cyclosporine A as treatment of esophageal involvement in dermatomyositis

  2006cited by this paper
• Treatment of inflammatory myopathies

  2006cited by this paper
• Treatment of refractory polymyositis and dermatomyositis

  2006cited by this paper
• Treatment of recalcitrant hidradenitis suppurativa with oral ciclosporin

  2006cited by this paper
• Behçet Disease: Recommendation for Clinical Management of Mucocutaneous Lesions

  2006cited by this paper
• [Extended cyclosporine-A--treatment for severe chronic urticaria].

  2006cited by this paper
• CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications—results of a retrospective analysis of 117 cases

  2006cited by this paper
• Update on the use of ciclosporin in immune‐mediated dermatoses

  2006cited by this paper
• Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.

  2006cited by this paper
• Oral Lichen Planus in Childhood

  2005cited by this paper
• Biological effects of cyclosporin A: A new antilymphocytic agent

  2005cited by this paper
• Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients.

  2005cited by this paper
• Cyclosporine controls epidermolysis bullosa acquisita co‐occurring with acquired factor VIII deficiency

  2005cited by this paper
• Prurigo nodularis: A review

  2005cited by this paper
• Polymyositis/dermatomyositis and interstitial lung disease: A new therapeutic approach with T-cell-specific immunosuppressants

  2005cited by this paper
• Alopecia areata in Down syndrome: a clinical evaluation

  2005cited by this paper
• Rationale for T Cell Inhibition by Cyclosporin A in Major Autoimmune Diseases

  2005cited by this paper
• Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine.

  2005cited by this paper
• Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines".

  2004cited by this paper
• Eosinophilic Pustular Folliculitis

  2004cited by this paper
• Ciclosporin in psoriasis clinical practice: an international consensus statement

  2004cited by this paper
• Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria.

  2004cited by this paper
• [Ocular Behçet disease. Retrospective study].

  2004cited by this paper
• A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

  2004cited by this paper
• Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A

  2004cited by this paper
• Guidelines of care for atopic dermatitis

  2004cited by this paper
• Chronic urticaria: pathogenesis and treatment.

  2004cited by this paper
• Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities

  2004cited by this paper
• Juvenile pityriasis rubra pilaris: successful treatment with ciclosporin

  2003cited by this paper
• Behçet's disease with relapsing cutaneous polyarteritis-nodosa-like lesions, responsive to oral cyclosporine therapy.

  2003cited by this paper
• Short course of oral cyclosporine in lichen planopilaris.

  2003cited by this paper
• Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation.

  2003cited by this paper
• Guidelines for the management of pemphigus vulgaris

  2003cited by this paper
• Long-term therapy with low dose cyclosporin A in ocular Behçet's disease*

  2002cited by this paper
• Schnitzler's syndrome with monoclonal IgG kappa gammopathy: good response to cyclosporin.

  2002cited by this paper
• Chronic actinic dermatitis treated with cyclosporine-A.

  2002cited by this paper
• Urticaria and cyclosporine

  2002cited by this paper
• Polymorphic light eruption treated with cyclosporin

  2001influential reference
• Graham Little–Piccardi–Lassueur syndrome: effective treatment with cyclosporin A

  2001cited by this paper
• Epidermolysis bullosa acquisita responsive to cyclosporin therapy

  2001cited by this paper
• [Severe chronic actinic dermatitis treated with cyclosporine: 2 cases].

  2001cited by this paper
• Cyclosporin for Atopic Dermatitis in Children

  2001cited by this paper
• Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.

  2001cited by this paper
• Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.

  2001cited by this paper
• Emerging treatment for epidermolysis bullosa acquisita.

  2001cited by this paper
• Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis

  2001cited by this paper
• Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma.

  2000cited by this paper
• Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus.

  2000cited by this paper
• Three Cases of Pityriasis rubra pilaris Successfully Treated with Cyclosporin A

  2000cited by this paper
• Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy

  2000cited by this paper
• Molecular targets for existing and novel immunosuppressive drugs

  2000cited by this paper
• A systematic review of treatments for severe psoriasis.

  2000cited by this paper
• Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy.

  1999cited by this paper
• Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1‐year multicentre, randomized study

  1999cited by this paper
• Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

  1999cited by this paper
• Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis

  1999cited by this paper
• Acitretin combination therapy.

  1999cited by this paper
• Cyclosporin in Atopic Dermatitis

  1999cited by this paper
• The efficacy, tolerability and safety of a new oral formulation of Sandimmun®‐Sandimmun Neoral® in severe refractory atopic dermatitis

  1998cited by this paper
• Treatment of lichen planus. An evidence-based medicine analysis of efficacy.

  1998cited by this paper
• Cyclosporine consensus conference: with emphasis on the treatment of psoriasis.

  1998influential reference
• Surgery and cyclosporine A in the treatment of erosive lichen planus of the feet.

  1998cited by this paper
• Double‐blind placebo‐controlled study of long‐term low‐dose cyclosporin in the treatment of palmoplantar pustulosis

  1998cited by this paper
• Long‐term efficacy and safety of cyclosporin in severe adult atopic dermatitis

  1997cited by this paper

• Cyclosporine use in paediatric dermatologic conditions: A comprehensive review of therapeutic applications.

  2026cites this paper
• Advances in LC-MS/MS methods and sample preparation strategies for therapeutic drug monitoring of immunosuppressive drugs.

  2026cites this paper
• Vitiligo: A Review of Pathogenesis and Treatments, Including New Therapies on the Horizon

  2025cites this paper
• Alopecia Areata: Pathogenesis, current treatments, and future perspectives

  2025cites this paper
• Treatment and referral patterns of patients with atopic dermatitis from the Danish primary care system to the tertiary care system

  2024cites this paper
• Celastrol regulates psoriatic inflammation and autophagy by targeting IL-17A.

  2024cites this paper
• Medical treatment of vitiligo: A narrative review

  2024cites this paper
• Lifitegrast, a Lymphocyte Function‐Associated Antigen‐1 Antagonist Demonstrates Beneficial Effect in Psoriasis

  2024cites this paper
• Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma.

  2024cites this paper
• "Dupilumab Treatment Decreases MBC2s, Correlating with Reduced IgE Levels in Pediatric AD".

  2024cites this paper
• Bio-synthesis, purification and structural analysis of Cyclosporine-A produced by Tolypocladium inflatum with valorization of agro-industrial wastes

  2024cites this paper
• The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids

  2024cites this paper
• Risk of Developing Hypertension in Atopic Dermatitis Patients Receiving Long-term and Low-dose Cyclosporine: A Nationwide Population-based Cohort Study

  2024cites this paper
• A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo

  2024cites this paper
• Identification of Keratinocyte Cytoprotectants against Toxicity by the Multikinase Inhibitor Sorafenib Using Drug Repositioning

  2024cites this paper
• Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents

  2023cites this paper
• Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems.

  2023cites this paper
• Therapeutic Options to Refractory Alopecia Areata

  2023cites this paper
• Comparison of cyclosporine and systemic corticosteroid for treating drug reaction with eosinophilia and systemic symptoms syndrome: A retrospective 20‐year single‐centre study in South Korea

  2023cites this paper
• Atopic Dermatitis in the Adult Population

  2023cites this paper
• Dermatomyositis: a comprehensive review of clinical manifestations, serological features, and therapeutic approaches.

  2023cites this paper
• Nail lichen planus treatment safety

  2023cites this paper
• The Effect of Calcineurin Inhibitors on MMPs Activity in Heart and Their Side Effects—A Review of Literature

  2023cites this paper
• Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress

  2023cites this paper
• Combination of cyclosporine A and methylprednisolone to treat pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome

  2023cites this paper
• Epidermólise bolhosa adquirida

  2022cites this paper
• Deucravacitinib in the treatment of psoriasis

  2022cites this paper
• Pathogenesis, multi-omics research, and clinical treatment of psoriasis.

  2022cites this paper
• Chronic Non-Healing Ulcers Associated with Atopic Inflammation: A Case Report

  2022cites this paper
• A comprehensive review of immunosuppressive drugs in pediatric dermatoses: Part I - Corticosteroids, azathioprine, and cyclosporine-A

  2022cites this paper
• Epidermolysis bullosa acquisita

  2022cites this paper
• Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP)

  2022cites this paper
• A systematic review of the efficacy and safety of topical cyclosporine in dermatology

  2022cites this paper
• Successful treatment of recalcitrant facial sebopsoriasis with low‐dose cyclosporine

  2022cites this paper
• Effect of immobilization, mutation, and microbial stresses on increasing production efficiency of “Cyclosporin A”

  2022cites this paper
• Systemic therapies in vitiligo: a review

  2022cites this paper
• Ca2+ Signalling Differentially Regulates Germ-Tube Formation and Cell Fusion in Fusarium oxysporum

  2022cites this paper
• Iatrogenic Disease and Drug Induced Toxicities Related to Anti-Inflammatory and Immunomodulatory Agents

  2022cites this paper
• Dermatomyositis

  2022cites this paper
• Cyclosporine

  2021cites this paper
• Atopic dermatitis. Clinical guidelines

  2021cites this paper
• Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.

  2021cites this paper
• Successful treatment of corticosteroid-dependent drug reaction with eosinophilia and systemic symptoms with cyclosporine.

  2021cites this paper
• Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options

  2021cites this paper
• Treatment of atopic dermatitis in pregnant women

  2021cites this paper
• Effect of Cyclosporine A on Dermal Fibroblast Cell - Transcriptomic Analysis of Inflammatory Response Pathway.

  2020cites this paper
• Safety considerations when using drugs to treat pruritus

  2020cites this paper
• Computational study for suppression of CD25/IL-2 interaction

  2020cites this paper
• Immunosuppressive and Immunomodulating Therapy for Atopic Dermatitis in Pregnancy: An Appraisal of the Literature

  2020cites this paper
• Systemic treatment of psoriasis: from methotrexate to biologics

  2020cites this paper
• The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections

  2020cites this paper
• Joint Aad-Npf Guidelines Of Care For The Management Of Psoriasis With Systemic Non-Biological Therapies.

  2020cites this paper
• Thrush: Weak children

  2020cites this paper
• Guidelines for the Diagnosis and Treatment of Psoriasis in China: 2019 Concise Edition#

  2020cites this paper
• Effective Treatment of Refractory Chronic Spontaneous Urticaria with Add-On Omalizumab and Ciclosporin: From Guideline to Real-Life Practice

  2020cites this paper
• Freeze-Dried Softisan® 649-Based Lipid Nanoparticles for Enhanced Skin Delivery of Cyclosporine A

  2020cites this paper
• The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 2. Management of H1-Antihistamine-Refractory Chronic Urticaria

  2020cites this paper
• Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review

  2020cites this paper
• Cardiovascular Side Effects of Medications for Skin Diseases

  2020cites this paper
• Safety and efficacy profile of oral cyclosporine vs oral methotrexate vs oral acitretin in palmoplantar psoriasis: A hospital based prospective investigator blind randomized controlled comparative study

  2020cites this paper
• Homocysteine and psoriasis

  2019cites this paper
• Ultraflexible lipid vesicles allow topical absorption of cyclosporin A

  2019cites this paper
• Comparison of cyclosporine and betamethasone minipulse therapy in management of Alopecia Areata

  2019cites this paper
• Systemic Therapy in Paediatric Dermatology

  2019cites this paper
• Pustular Forms of Psoriasis Related to Autoinflammation

  2019cites this paper
• Outcomes of prolonged and low-dose ciclosporin in an Asian population

  2019cites this paper
• Acute form of acne inversa in an 18-week pregnant patient: a case study

  2019cites this paper
• Itch

  2019cites this paper
• Hyperpigmentation Due to Cyclosporine Therapy

  2019cites this paper
• European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period

  2019cites this paper
• Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine

  2019cites this paper
• Potential Mechanism of Action of Cyclosporin A in Human Dermal Fibroblasts—Transcriptomic Analysis of CYPs

  2018cites this paper
• Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment

  2018cites this paper
• A meta-analysis of cyclosporine treatment for Stevens–Johnson syndrome/toxic epidermal necrolysis

  2018cites this paper
• Practical Management of Immunosuppressants in Dermatology.

  2018cites this paper
• Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP

  2018cites this paper
• Influence of protamine shell on nanoemulsions as a carrier for cyclosporine-A skin delivery

  2018cites this paper
• Guías clínicas chilenas para el manejo de la psoriasis

  2018cites this paper
• Manejo práctico de inmunosupresores en dermatología

  2018cites this paper
• Tratamento da Dermite Atópica Moderada a Grave em Adultos

  2018cites this paper
• Therapeutic Efficacy of Combination Therapy Using Oral Cyclosporine with a Dietary Supplement (Pantogar®) in Twenty-Nail Dystrophy

  2017cites this paper
• Assessment of the effectiveness of cyclosporine nasal spray in an animal model of allergic rhinitis

  2017cites this paper
• The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review

  2017cites this paper
• Cyclosporine in the Treatment of Psoriasis

  2017cites this paper
• Immune Parameters of Korean Patients with Psoriasis Treated with Low-Dose Cyclosporine

  2017cites this paper
• A clinical audit of high‐cost and off‐label drug use in dermatology

  2017cites this paper
• Efficacy of Cyclosporine After Autologous Noncultured Melanocyte Transplantation in Localized Stable Vitiligo—A Pilot, Open Label, Comparative Study

  2017cites this paper
• Psoriasis & psoriatic therapies

  2017cites this paper
• A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis.

  2017cites this paper
• Importance of concomitant topical therapy in moderate‐to‐severe atopic dermatitis treated with cyclosporine

  2016cites this paper
• New Oral Therapies for Psoriasis: A Comprehensive Review.

  2016cites this paper
• Consensus Conference on Clinical Management of pediatric Atopic Dermatitis

  2016cites this paper
• An Update on Medical Treatment Options for Hidradenitis Suppurativa

  2016cites this paper
• Cyclosporine in toxic epidermal necrolysis: a brief review of the emerging therapeutic modality.

  2016influential citation
• Anti-IL-17A blocking antibody reduces cyclosporin A-induced relapse in experimental autoimmune encephalomyelitis mice

  2016cites this paper
• Current and Emerging Therapies for Itch Management in Psoriasis

  2016cites this paper
• Facial hair growth in a patient with psoriasis.

  2016cites this paper
• Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications

  2016cites this paper
• Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines.

  2016cites this paper
• A Patient with Refractory Psoriasis Who Developed Sebaceous Carcinoma on the Neck during Cyclosporine Therapy and Showed Rapid Progression

  2016cites this paper